25 XP   0   0   10

Larimar Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Larimar Therapeutics Inc together

PenkeI guess you are interested in Larimar Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Larimar Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Larimar Therapeutics Inc

I send you an email if I find something interesting about Larimar Therapeutics Inc.

Quick analysis of Larimar Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Larimar Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.28
Expected worth in 1 year
$0.82
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.46
Return On Investment
-6.5%

For what price can you sell your share?

Current Price per Share
$7.08
Expected price per share
$5.52 - $11.97
How sure are you?
50%

1. Valuation of Larimar Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$7.08

Intrinsic Value Per Share

$-3.82 - $-4.37

Total Value Per Share

$-2.54 - $-3.09

2. Growth of Larimar Therapeutics Inc (5 min.)




Is Larimar Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$81.7m$84.1m$10.9m11.5%

How much money is Larimar Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$8.9m-$8.5m-$413.5k-4.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Larimar Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#403 / 998

Most Revenue
#781 / 998

Most Profit
#563 / 998

Most Efficient
#197 / 998

What can you expect buying and holding a share of Larimar Therapeutics Inc? (5 min.)

Welcome investor! Larimar Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Larimar Therapeutics Inc.

What can you expect buying and holding a share of Larimar Therapeutics Inc?

First you should know what it really means to hold a share of Larimar Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Larimar Therapeutics Inc is $7.08. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Larimar Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Larimar Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.28. Based on the TTM, the Book Value Change Per Share is $-0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Larimar Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.20-2.9%-0.14-2.0%-0.14-2.0%-0.15-2.1%-0.11-1.5%
Usd Book Value Change Per Share-0.17-2.4%-0.11-1.6%0.182.6%0.060.9%0.050.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.17-2.4%-0.11-1.6%0.182.6%0.060.9%0.050.6%
Usd Price Per Share4.55-4.04-3.34-6.61-7.49-
Price to Earnings Ratio-5.59--7.39--5.99--10.04--1,296.90-
Price-to-Total Gains Ratio-26.41--38.74--21.02--22.19--1,161.61-
Price to Book Ratio3.55-2.75-2.78-1,088.68-1,317.03-
Price-to-Total Gains Ratio-26.41--38.74--21.02--22.19--1,161.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.08
Number of shares141
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.110.06
Usd Total Gains Per Share-0.110.06
Gains per Quarter (141 shares)-16.129.01
Gains per Year (141 shares)-64.5036.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-64-7403626
20-129-13807262
30-193-202010898
40-258-2660144134
50-322-3300180170
60-387-3940216206
70-451-4580252242
80-516-5220288278
90-580-5860324314
100-645-6500360350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.028.00.00.0%0.028.00.00.0%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%7.021.00.025.0%7.021.00.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.028.00.0%0.00.028.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.015.00.025.0%7.021.00.025.0%7.021.00.025.0%

Fundamentals of Larimar Therapeutics Inc

About Larimar Therapeutics Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Fundamental data was last updated by Penke on 2024-05-02 23:21:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Larimar Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Larimar Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Larimar Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--211.9%+211.9%
YOY--263.3%+263.3%
5Y--414.0%+414.0%
10Y--552.3%+552.3%
1.1.2. Return on Assets

Shows how efficient Larimar Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • -13.5% Return on Assets means that Larimar Therapeutics Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Larimar Therapeutics Inc:

  • The MRQ is -13.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.5%TTM-8.6%-5.0%
TTM-8.6%YOY-9.8%+1.2%
TTM-8.6%5Y-4,787.3%+4,778.7%
5Y-4,787.3%10Y-3,422.7%-1,364.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.5%-11.9%-1.6%
TTM-8.6%-11.5%+2.9%
YOY-9.8%-10.9%+1.1%
5Y-4,787.3%-13.1%-4,774.2%
10Y-3,422.7%-14.4%-3,408.3%
1.1.3. Return on Equity

Shows how efficient Larimar Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • -15.9% Return on Equity means Larimar Therapeutics Inc generated $-0.16 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Larimar Therapeutics Inc:

  • The MRQ is -15.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.9%TTM-9.8%-6.1%
TTM-9.8%YOY-11.9%+2.1%
TTM-9.8%5Y-14,810.5%+14,800.7%
5Y-14,810.5%10Y-10,582.8%-4,227.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.9%-15.3%-0.6%
TTM-9.8%-14.6%+4.8%
YOY-11.9%-13.6%+1.7%
5Y-14,810.5%-17.7%-14,792.8%
10Y-10,582.8%-19.2%-10,563.6%

1.2. Operating Efficiency of Larimar Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Larimar Therapeutics Inc is operating .

  • Measures how much profit Larimar Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Larimar Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--336.0%+336.0%
TTM--224.0%+224.0%
YOY--280.1%+280.1%
5Y--412.2%+412.2%
10Y--521.7%+521.7%
1.2.2. Operating Ratio

Measures how efficient Larimar Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Larimar Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.005-3.005
TTM-3.247-3.247
YOY-3.619-3.619
5Y-5.262-5.262
10Y-6.874-6.874

1.3. Liquidity of Larimar Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Larimar Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.49 means the company has $9.49 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Larimar Therapeutics Inc:

  • The MRQ is 9.486. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.326. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.486TTM13.326-3.840
TTM13.326YOY9.859+3.467
TTM13.3265Y9.630+3.696
5Y9.63010Y10.881-1.251
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.4863.805+5.681
TTM13.3264.158+9.168
YOY9.8595.252+4.607
5Y9.6306.087+3.543
10Y10.8816.434+4.447
1.3.2. Quick Ratio

Measures if Larimar Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 15.45 means the company can pay off $15.45 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Larimar Therapeutics Inc:

  • The MRQ is 15.446. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.094. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.446TTM17.094-1.648
TTM17.094YOY13.941+3.153
TTM17.0945Y297.667-280.573
5Y297.66710Y219.134+78.533
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4463.202+12.244
TTM17.0943.816+13.278
YOY13.9415.183+8.758
5Y297.6675.929+291.738
10Y219.1346.351+212.783

1.4. Solvency of Larimar Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Larimar Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Larimar Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Larimar Therapeutics Inc assets are financed with 14.8% credit (debt) and the remaining percentage (100% - 14.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Larimar Therapeutics Inc:

  • The MRQ is 0.148. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.117. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.148TTM0.117+0.031
TTM0.117YOY0.158-0.041
TTM0.1175Y0.243-0.125
5Y0.24310Y0.216+0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1480.344-0.196
TTM0.1170.342-0.225
YOY0.1580.279-0.121
5Y0.2430.366-0.123
10Y0.2160.380-0.164
1.4.2. Debt to Equity Ratio

Measures if Larimar Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 17.4% means that company has $0.17 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Larimar Therapeutics Inc:

  • The MRQ is 0.174. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.133. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.174TTM0.133+0.041
TTM0.133YOY0.191-0.058
TTM0.1335Y477.648-477.515
5Y477.64810Y341.232+136.416
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1740.398-0.224
TTM0.1330.415-0.282
YOY0.1910.353-0.162
5Y477.6480.446+477.202
10Y341.2320.470+340.762

2. Market Valuation of Larimar Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Larimar Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Larimar Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -5.59 means the investor is paying $-5.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Larimar Therapeutics Inc:

  • The EOD is -8.691. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.586. Based on the earnings, the company is expensive. -2
  • The TTM is -7.394. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.691MRQ-5.586-3.106
MRQ-5.586TTM-7.394+1.808
TTM-7.394YOY-5.989-1.405
TTM-7.3945Y-10.036+2.642
5Y-10.03610Y-1,296.904+1,286.868
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.691-2.313-6.378
MRQ-5.586-2.535-3.051
TTM-7.394-2.723-4.671
YOY-5.989-3.958-2.031
5Y-10.036-6.316-3.720
10Y-1,296.904-6.544-1,290.360
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Larimar Therapeutics Inc:

  • The EOD is -11.878. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.634. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.707. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.878MRQ-7.634-4.245
MRQ-7.634TTM-7.707+0.074
TTM-7.707YOY-7.813+0.106
TTM-7.7075Y-684.997+677.290
5Y-684.99710Y-1,557.700+872.703
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.878-3.099-8.779
MRQ-7.634-3.270-4.364
TTM-7.707-3.523-4.184
YOY-7.813-5.220-2.593
5Y-684.997-8.080-676.917
10Y-1,557.700-8.637-1,549.063
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Larimar Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.55 means the investor is paying $3.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Larimar Therapeutics Inc:

  • The EOD is 5.527. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.552. Based on the equity, the company is fair priced.
  • The TTM is 2.747. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.527MRQ3.552+1.975
MRQ3.552TTM2.747+0.805
TTM2.747YOY2.780-0.033
TTM2.7475Y1,088.684-1,085.937
5Y1,088.68410Y1,317.026-228.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.5272.009+3.518
MRQ3.5522.029+1.523
TTM2.7472.065+0.682
YOY2.7802.688+0.092
5Y1,088.6843.688+1,084.996
10Y1,317.0264.095+1,312.931
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Larimar Therapeutics Inc.

3.1. Institutions holding Larimar Therapeutics Inc

Institutions are holding 84.763% of the shares of Larimar Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Deerfield Management Co26.61951.47441694135700
2023-12-31Blue Owl Capital Holdings LP5.36513.7137341446834144680
2023-09-30CHI Advisors LLC5.36515.3455341446800
2023-12-31Verition Fund Managegment, LLC4.4170.10012811131-89407-3.0824
2023-12-31HHG PLC4.14980.007226410651796037.2966
2023-12-31BlackRock Inc2.6210.0002166804515923010.5533
2023-12-31Vanguard Group Inc2.28660.00011455243275161.9273
2023-12-31Adage Capital Partners Gp LLC2.0060.01212766801000008.4985
2023-09-30Citadel Advisors Llc1.53860.0008979186-197469-16.7822
2023-12-31Mangrove Partners1.26620.247780581500
2023-12-31Woodline Partners LP1.25110.03947962268654512.1949
2023-12-31StemPoint Capital LP1.23060.95077831727831720
2023-12-31Geode Capital Management, LLC1.01770.0003647718314125.0968
2023-12-31Opaleye Management Inc0.97970.7544623500-225000-26.5174
2023-12-31Ikarian Capital, LLC0.94730.2568602868-80000-11.7153
2023-12-31State Street Corporation0.73080.0001465117114002.5126
2023-09-30Point72 Asset Management, L.P.0.71490.0052455000-384000-45.7688
2023-12-31Dafna Capital Management LLC0.50890.3531323873-3500-1.0691
2023-12-31UBS O'Connor LLC0.50270.1047319901-58604-15.483
2023-12-31Atlas Venture Advisors, Inc.0.45910.233729218400
Total 63.977713.600140717017+3755366+9.2%

3.2. Funds holding Larimar Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.10.001133982152840065.1203
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.29050.0059823331121881.5026
2024-03-28iShares Russell 2000 ETF1.00550.00746415053090.0482
2024-02-29Janus Henderson Hrzn Biotec E2 USD0.50761.41343238773238770
2024-02-29Heptagon Driehaus US Micro Cap Eq C$ Acc0.46180.41652946322946320
2024-01-31Fidelity Small Cap Index0.41080.0061262066157686.402
2023-12-31Xtrackers S&P Global Infra Swap ETF 1C0.40060.528425559300
2024-03-28iShares Russell 2000 Value ETF0.38040.0147242705-154-0.0634
2024-02-29Fidelity Extended Market Index0.31060.0059198173-12135-5.7701
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.25090.002816010000
2024-03-31Alger Small Cap Growth Composite0.24080.95431536101536100
2024-01-31Alger LIfe Sciences Innovation Composite0.22153.69281413165475563.256
2023-12-31Bridgeway Ultra-Small Company Market0.18290.285811670067006.0909
2024-03-31BlackRock Extended Equity Market K0.180.0061148275517592.4948
2024-02-29Allianz Biotechnologie P EUR0.1620.30841033601033600
2024-02-29Fidelity Total Market Index0.15460.0013986193714760.4291
2024-03-31Vanguard Russell 2000 ETF0.15360.00739799659036.4098
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.14670.00739360000
2024-02-29Driehaus Micro Cap Growth0.13750.418587747877470
2023-12-31NT R2000 Value Index Fund - NL0.12180.00947768700
Total 8.82018.09325627265+1667282+29.6%

3.3. Insider Transactions

Insiders are holding 1.45% of the shares of Larimar Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-16James E FlynnBUY42906178.74
2024-02-14Frank E ThomasBUY200011
2023-05-17Joseph TruittBUY27503.73
2023-05-17Michael CelanoBUY50003.73

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Larimar Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.172-0.114-34%0.182-195%0.064-370%0.046-477%
Book Value Per Share--1.2811.491-14%1.319-3%1.190+8%0.851+50%
Current Ratio--9.48613.326-29%9.859-4%9.630-1%10.881-13%
Debt To Asset Ratio--0.1480.117+27%0.158-6%0.243-39%0.216-31%
Debt To Equity Ratio--0.1740.133+31%0.191-9%477.648-100%341.232-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.204-0.145-29%-0.139-32%-0.149-27%-0.106-48%
Free Cash Flow Per Share---0.149-0.132-12%-0.108-27%-0.125-16%-0.090-40%
Free Cash Flow To Equity Per Share---0.149-0.132-12%0.779-119%0.227-166%0.162-192%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.366--------
Intrinsic Value_10Y_min---3.821--------
Intrinsic Value_1Y_max---0.528--------
Intrinsic Value_1Y_min---0.518--------
Intrinsic Value_3Y_max---1.516--------
Intrinsic Value_3Y_min---1.449--------
Intrinsic Value_5Y_max---2.423--------
Intrinsic Value_5Y_min---2.255--------
Market Cap451704000.000+36%290290000.000257752000.000+13%212773000.000+36%421810510.000-31%74256899559.286-100%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio5.527+36%3.5522.747+29%2.780+28%1088.684-100%1317.026-100%
Pe Ratio-8.691-56%-5.586-7.394+32%-5.989+7%-10.036+80%-1296.904+23119%
Price Per Share7.080+36%4.5504.040+13%3.335+36%6.611-31%7.488-39%
Price To Free Cash Flow Ratio-11.878-56%-7.634-7.707+1%-7.813+2%-684.997+8873%-1557.700+20306%
Price To Total Gains Ratio-41.094-56%-26.409-38.740+47%-21.020-20%-22.191-16%-1161.609+4299%
Quick Ratio--15.44617.094-10%13.941+11%297.667-95%219.134-93%
Return On Assets---0.135-0.086-37%-0.098-28%-47.873+35247%-34.227+25172%
Return On Equity---0.159-0.098-38%-0.119-25%-148.105+93051%-105.828+66461%
Total Gains Per Share---0.172-0.114-34%0.182-195%0.064-370%0.046-477%
Usd Book Value--81720000.00095150750.000-14%84181500.000-3%75934312.800+8%90459973.429-10%
Usd Book Value Change Per Share---0.172-0.114-34%0.182-195%0.064-370%0.046-477%
Usd Book Value Per Share--1.2811.491-14%1.319-3%1.190+8%0.851+50%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.204-0.145-29%-0.139-32%-0.149-27%-0.106-48%
Usd Free Cash Flow---9507000.000-8405750.000-12%-6917250.000-27%-7989299.900-16%-9697499.929+2%
Usd Free Cash Flow Per Share---0.149-0.132-12%-0.108-27%-0.125-16%-0.090-40%
Usd Free Cash Flow To Equity Per Share---0.149-0.132-12%0.779-119%0.227-166%0.162-192%
Usd Market Cap451704000.000+36%290290000.000257752000.000+13%212773000.000+36%421810510.000-31%74256899559.286-100%
Usd Price Per Share7.080+36%4.5504.040+13%3.335+36%6.611-31%7.488-39%
Usd Profit---12993000.000-8959500.000-31%-8546000.000-34%-9077586.200-30%-10821240.143-17%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.172-0.114-34%0.182-195%0.064-370%0.046-477%
 EOD+5 -3MRQTTM+4 -25YOY+6 -235Y+9 -2010Y+10 -19

4.2. Fundamental Score

Let's check the fundamental score of Larimar Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.691
Price to Book Ratio (EOD)Between0-15.527
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than115.446
Current Ratio (MRQ)Greater than19.486
Debt to Asset Ratio (MRQ)Less than10.148
Debt to Equity Ratio (MRQ)Less than10.174
Return on Equity (MRQ)Greater than0.15-0.159
Return on Assets (MRQ)Greater than0.05-0.135
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Larimar Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.424
Ma 20Greater thanMa 507.549
Ma 50Greater thanMa 1007.411
Ma 100Greater thanMa 2007.603
OpenGreater thanClose7.450
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets95,935
Total Liabilities14,215
Total Stockholder Equity81,720
 As reported
Total Liabilities 14,215
Total Stockholder Equity+ 81,720
Total Assets = 95,935

Assets

Total Assets95,935
Total Current Assets90,175
Long-term Assets5,760
Total Current Assets
Cash And Cash Equivalents 26,749
Short-term Investments 60,041
Other Current Assets 3,385
Total Current Assets  (as reported)90,175
Total Current Assets  (calculated)90,175
+/-0
Long-term Assets
Property Plant Equipment 3,762
Long-term Assets Other 659
Long-term Assets  (as reported)5,760
Long-term Assets  (calculated)4,421
+/- 1,339

Liabilities & Shareholders' Equity

Total Current Liabilities9,506
Long-term Liabilities4,709
Total Stockholder Equity81,720
Total Current Liabilities
Short-term Debt 837
Accounts payable 1,283
Other Current Liabilities 7,386
Total Current Liabilities  (as reported)9,506
Total Current Liabilities  (calculated)9,506
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt4,709
Long-term Liabilities  (as reported)4,709
Long-term Liabilities  (calculated)4,709
+/-0
Total Stockholder Equity
Common Stock43
Retained Earnings -188,554
Accumulated Other Comprehensive Income 81
Other Stockholders Equity 270,150
Total Stockholder Equity (as reported)81,720
Total Stockholder Equity (calculated)81,720
+/-0
Other
Capital Stock43
Cash and Short Term Investments 86,790
Common Stock Shares Outstanding 43,906
Liabilities and Stockholders Equity 95,935
Net Debt -21,203
Net Invested Capital 81,720
Net Working Capital 80,669
Property Plant and Equipment Gross 4,987
Short Long Term Debt Total 5,546



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-30
> Total Assets 
136,968
129,636
117,519
236,721
222,602
207,447
189,106
170,032
154,826
142,712
131,621
119,371
108,845
96,264
105,510
92,614
79,800
131,945
121,762
110,185
103,884
92,887
5,201
7
125,457
113,957
104,686
93,019
80,931
87,938
78,667
71,223
62,852
133,015
126,405
118,907
111,716
103,952
95,935
95,935103,952111,716118,907126,405133,01562,85271,22378,66787,93880,93193,019104,686113,957125,45775,20192,887103,884110,185121,762131,94579,80092,614105,51096,264108,845119,371131,621142,712154,826170,032189,106207,447222,602236,721117,519129,636136,968
   > Total Current Assets 
136,822
129,469
117,198
236,326
221,630
206,090
188,110
168,844
153,152
141,575
130,899
118,682
107,965
95,656
104,925
91,422
78,033
131,469
121,330
4
94,001
83,443
4,750
6
119,111
107,816
97,952
86,127
74,036
81,253
72,204
64,879
56,744
127,127
120,739
113,464
106,478
98,480
90,175
90,17598,480106,478113,464120,739127,12756,74464,87972,20481,25374,03686,12797,952107,816119,11164,75083,44394,0014121,330131,46978,03391,422104,92595,656107,965118,682130,899141,575153,152168,844188,110206,090221,630236,326117,198129,469136,822
       Cash And Cash Equivalents 
134,233
127,030
58,103
106,934
83,573
38,763
35,595
31,450
20,026
24,861
32,352
28,632
31,726
19,193
40,777
45,731
40,745
45,141
49,331
-4
37,240
43,337
1,009
1
112,673
101,308
68,148
62,193
70,630
71,525
70,097
62,564
19,736
86,047
26,825
111,524
94,321
38,721
26,749
26,74938,72194,321111,52426,82586,04719,73662,56470,09771,52570,63062,19368,148101,308112,67311,00943,33737,240-449,33145,14140,74545,73140,77719,19331,72628,63232,35224,86120,02631,45035,59538,76383,573106,93458,103127,030134,233
       Short-term Investments 
0
0
57,359
127,267
136,547
165,191
149,484
134,734
130,442
113,796
96,842
88,304
74,266
73,987
61,275
43,339
35,104
82,691
68,735
9
54,418
38,669
43,050
24,905
1,011
1,001
24,490
19,245
0
6,499
0
0
35,188
38,652
91,603
0
9,879
56,869
60,041
60,04156,8699,879091,60338,65235,188006,499019,24524,4901,0011,01124,90543,05038,66954,418968,73582,69135,10443,33961,27573,98774,26688,30496,842113,796130,442134,734149,484165,191136,547127,26757,35900
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,550
1,532
235
158
214
55
34
32
107
67
219
208
323
237
114
0
300
300
0
0
003003000114237323208219671073234552141582351,5321,5500000000000000000000
       Other Current Assets 
2,589
2,439
1,736
2,125
1,510
2,136
3,031
2,660
2,684
2,918
1,705
1,746
1,973
2,476
2,873
2,352
2,184
3,637
3,264
1,259
811
1,202
419
5
5,427
5,507
5,314
4,582
3,339
3,010
2,107
1,992
1,583
2,314
2,311
1,940
2,278
2,890
3,385
3,3852,8902,2781,9402,3112,3141,5831,9922,1073,0103,3394,5825,3145,5075,42754191,2028111,2593,2643,6372,1842,3522,8732,4761,9731,7461,7052,9182,6842,6603,0312,1361,5102,1251,7362,4392,589
   > Long-term Assets 
146
167
321
395
972
1,357
996
1,188
1,674
1,137
722
689
880
608
585
1,192
1,767
476
432
-4
9,883
9,444
451
1
6,346
6,141
6,734
6,892
6,895
6,685
6,463
6,344
6,108
5,888
5,666
5,443
5,238
5,472
5,760
5,7605,4725,2385,4435,6665,8886,1086,3446,4636,6856,8956,8926,7346,1416,34614519,4449,883-44324761,7671,1925856088806897221,1371,6741,1889961,357972395321167146
       Property Plant Equipment 
42
69
79
101
215
303
902
954
1,256
722
661
630
588
551
528
479
472
419
375
1,220
8,310
8,085
361
1
4,927
4,724
4,976
4,803
4,884
4,675
4,455
4,337
4,120
3,906
3,689
3,472
3,255
3,499
3,762
3,7623,4993,2553,4723,6893,9064,1204,3374,4554,6754,8844,8034,9764,7244,92713618,0858,3101,2203754194724795285515886306617221,256954902303215101796942
       Long-term Assets Other 
104
98
242
294
757
1,054
94
234
418
415
61
59
292
57
57
713
1,295
57
57
-1,224
1,573
1,359
90
0
1,419
1,417
1,758
750
672
671
669
668
649
643
638
632
644
634
659
6596346446326386436496686696716727501,7581,4171,4190901,3591,573-1,22457571,29571357572925961415418234941,05475729424298104
> Total Liabilities 
11,549
18,440
13,078
15,052
16,409
17,746
19,996
15,604
12,587
12,539
9,894
8,597
9,219
7,034
27,293
27,617
27,778
28,008
28,491
27,821
31,745
33,007
5,895
5
12,913
11,316
14,994
14,235
13,406
15,871
14,254
14,118
12,796
14,353
15,502
12,666
11,786
11,240
14,215
14,21511,24011,78612,66615,50214,35312,79614,11814,25415,87113,40614,23514,99411,31612,91355,89533,00731,74527,82128,49128,00827,77827,61727,2937,0349,2198,5979,89412,53912,58715,60419,99617,74616,40915,05213,07818,44011,549
   > Total Current Liabilities 
4,102
11,621
6,901
9,531
11,558
13,584
16,543
12,881
10,614
11,339
9,894
8,597
9,219
7,034
7,293
7,457
9,276
11,164
13,306
13,728
13,463
16,339
5,895
4
6,645
5,178
8,992
8,375
7,691
10,306
8,846
8,873
7,719
9,420
10,705
8,010
7,275
6,558
9,506
9,5066,5587,2758,01010,7059,4207,7198,8738,84610,3067,6918,3758,9925,1786,64545,89516,33913,46313,72813,30611,1649,2767,4577,2937,0349,2198,5979,89411,33910,61412,88116,54313,58411,5589,5316,90111,6214,102
       Short-term Debt 
0
684
1,381
2,093
2,820
2,877
2,936
2,996
3,057
3,119
3,589
2,837
2,063
1,268
0
0
1,818
3,636
5,455
7,273
7,891
7,682
97
7,683
591
525
515
534
553
574
594
616
638
632
611
589
566
708
837
8377085665896116326386165945745535345155255917,683977,6827,8917,2735,4553,6361,818001,2682,0632,8373,5893,1193,0572,9962,9362,8772,8202,0931,3816840
       Accounts payable 
2,057
1,052
2,348
3,404
4,297
4,151
7,495
3,146
2,581
3,640
2,572
1,910
4,447
2,676
3,020
3,796
3,010
2,627
3,590
3,156
2,056
3,319
3,539
2
2,258
1,269
2,634
3,230
1,463
1,766
1,660
2,417
425
849
1,686
695
2,344
756
1,283
1,2837562,3446951,6868494252,4171,6601,7661,4633,2302,6341,2692,25823,5393,3192,0563,1563,5902,6273,0103,7963,0202,6764,4471,9102,5723,6402,5813,1467,4954,1514,2973,4042,3481,0522,057
       Other Current Liabilities 
2,045
9,885
3,172
4,034
4,441
6,556
6,112
6,739
4,976
4,580
3,733
3,850
2,709
3,090
4,273
3,661
4,448
4,901
4,261
10,572
11,407
13,020
11,461
3
3,796
3,384
5,843
4,611
5,675
7,966
6,592
5,840
6,656
7,939
8,408
6,726
4,365
5,094
7,386
7,3865,0944,3656,7268,4087,9396,6565,8406,5927,9665,6754,6115,8433,3843,796311,46113,02011,40710,5724,2614,9014,4483,6614,2733,0902,7093,8503,7334,5804,9766,7396,1126,5564,4414,0343,1729,8852,045
   > Long-term Liabilities 
7,447
6,819
6,177
5,521
4,851
4,162
3,453
2,723
1,973
1,200
0
0
0
0
20,000
20,160
18,502
16,844
15,185
14,093
18,282
16,668
14,920
0
6,268
6,138
6,002
5,860
5,715
5,565
5,408
5,245
5,077
4,933
4,797
4,656
4,511
4,682
4,709
4,7094,6824,5114,6564,7974,9335,0775,2455,4085,5655,7155,8606,0026,1386,268014,92016,66818,28214,09315,18516,84418,50220,16020,00000001,2001,9732,7233,4534,1624,8515,5216,1776,8197,447
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,526
11,853
10,166
8,464
6,747
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000006,7478,46410,16611,85313,5260000000000000000000
> Total Stockholder Equity
125,419
111,196
104,441
221,669
206,193
189,701
169,110
154,428
142,239
130,173
121,727
110,774
99,626
89,230
78,217
64,997
52,022
103,937
93,271
3
72,139
59,880
-694
2
112,544
102,641
89,692
78,784
67,525
72,067
64,413
57,105
50,056
118,662
110,903
106,241
99,930
92,712
81,720
81,72092,71299,930106,241110,903118,66250,05657,10564,41372,06767,52578,78489,692102,641112,5442-69459,88072,139393,271103,93752,02264,99778,21789,23099,626110,774121,727130,173142,239154,428169,110189,701206,193221,669104,441111,196125,419
   Common Stock
23
23
23
27
27
27
27
27
27
27
27
27
27
27
27
28
28
37
37
37
37
37
6
0
15
15
15
15
15
18
18
18
18
43
43
43
43
43
43
4343434343431818181815151515150637373737372828272727272727272727272727232323
   Retained Earnings -188,554-175,561-166,497-158,131-151,605-142,180-133,860-125,193-116,250-107,116-90,311-77,702-65,614-51,410-41,136-30-23,132-389,100-376,186-364,057-350,945-336,375-321,308-305,533-289,577-276,492-263,907-250,560-237,549-227,110-212,435-197,407-179,671-156,497-136,613-118,857-105,385-94,454-79,765
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
446,383
448,258
448,902
449,903
450,623
0
0
155,290
156,470
157,820
179,165
0
0
0
260,839
262,496
264,329
0
0
0
000264,329262,496260,839000179,165157,820156,470155,29000450,623449,903448,902448,258446,3830000000000000000000
   Treasury Stock000000000000000000000000000000000000000
   Other Stockholders Equity 
205,161
205,627
209,803
340,538
342,839
346,203
348,754
351,807
354,661
357,322
359,249
361,370
363,547
365,723
367,767
370,551
373,308
440,303
444,179
364,020
448,228
448,861
22,432
-30
153,668
154,038
155,290
156,470
157,820
179,165
180,645
182,280
183,955
260,839
262,496
264,329
266,372
268,223
270,150
270,150268,223266,372264,329262,496260,839183,955182,280180,645179,165157,820156,470155,290154,038153,668-3022,432448,861448,228364,020444,179440,303373,308370,551367,767365,723363,547361,370359,249357,322354,661351,807348,754346,203342,839340,538209,803205,627205,161



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-311
Gross Profit-311-311
 
Operating Income (+$)
Gross Profit-311
Operating Expense-41,447
Operating Income-41,758-41,758
 
Operating Expense (+$)
Research Development27,359
Selling General Administrative14
Selling And Marketing Expenses14,074
Operating Expense41,44741,447
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-41,758
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-36,949-46,567
EBIT - interestExpense = -41,758
-36,949
-36,949
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-41,758-36,949
Earnings Before Interest and Taxes (EBITDA)-41,447
 
After tax Income (+$)
Income Before Tax-36,949
Tax Provision-0
Net Income From Continuing Ops-36,949-36,949
Net Income-36,949
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses41,758
Total Other Income/Expenses Net4,8090
 

Technical Analysis of Larimar Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Larimar Therapeutics Inc. The general trend of Larimar Therapeutics Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Larimar Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Larimar Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 8.15 < 8.33 < 11.97.

The bearish price targets are: 7.04 > 5.91 > 5.52.

Tweet this
Larimar Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Larimar Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Larimar Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Larimar Therapeutics Inc. The current macd is 0.02006017.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Larimar Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Larimar Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Larimar Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Larimar Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLarimar Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Larimar Therapeutics Inc. The current adx is 14.99.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Larimar Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Larimar Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Larimar Therapeutics Inc. The current sar is 8.64864.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Larimar Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Larimar Therapeutics Inc. The current rsi is 44.42. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Larimar Therapeutics Inc Daily Relative Strength Index (RSI) ChartLarimar Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Larimar Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Larimar Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Larimar Therapeutics Inc Daily Stochastic Oscillator ChartLarimar Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Larimar Therapeutics Inc. The current cci is -71.89512383.

Larimar Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLarimar Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Larimar Therapeutics Inc. The current cmo is -17.65246363.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Larimar Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLarimar Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Larimar Therapeutics Inc. The current willr is -95.23241955.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Larimar Therapeutics Inc Daily Williams %R ChartLarimar Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Larimar Therapeutics Inc.

Larimar Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Larimar Therapeutics Inc. The current atr is 0.59954855.

Larimar Therapeutics Inc Daily Average True Range (ATR) ChartLarimar Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Larimar Therapeutics Inc. The current obv is 24,449,465.

Larimar Therapeutics Inc Daily On-Balance Volume (OBV) ChartLarimar Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Larimar Therapeutics Inc. The current mfi is 62.63.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Larimar Therapeutics Inc Daily Money Flow Index (MFI) ChartLarimar Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Larimar Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-05-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Larimar Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Larimar Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.424
Ma 20Greater thanMa 507.549
Ma 50Greater thanMa 1007.411
Ma 100Greater thanMa 2007.603
OpenGreater thanClose7.450
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Larimar Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Larimar Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Larimar Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Larimar Therapeutics Inc

I send you an email if I find something interesting about Larimar Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Larimar Therapeutics Inc.

Receive notifications about Larimar Therapeutics Inc in your mailbox!